Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Eli Lilly And Co — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.22, while Eli Lilly And Co trades at $1,215.24 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while Vanguard Total Bond Market Index Fund ETF pays none. Which is the better fit depends on your goals.
| BND | LLY | |
|---|---|---|
52-Week High | $75.17 | $1.24K |
52-Week Low | $72.15 | $639.43 |
Market Cap | — | $1.10T |
Sector | — | Health |
Enterprise Value | — | $1.14T |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.4, up 0.21% today, with a neutral technical signal from indicators like RSI near 50. Recent news highlights institutional activity, including Boston Standard Wealth reducing its stake by 30.6% in Q2 2026 (SEC filing, August 5, 2026), while Arkadios Wealth increased holdings by 41.9% (SEC filing, July 30, 2026). The bond ETF faces headwinds from rising Treasury yields and inflation concerns, as noted in financial media.
Outlook is cautious due to interest rate sensitivity and macroeconomic volatility. Risks include Fed policy shifts and oil price fluctuations, but BND offers diversification and steady dividends, with recent payouts around $0.24-$0.25. Investors should weigh income benefits against bond market pressures.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
